MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, TBPH has $485,570K in assets. $167,806K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
1092.53%
Quick Ratio
1092.53%
Cash Ratio
438.11%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Short-term marketable securities
    • Receivables from milestones and ...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Unrecognized tax benefits
    • Others

Balance Sheets
2025-12-31
Cash and cash equivalents
167,806
Short-term marketable securities
147,551
Receivables from collaborative arrangements
45,539
Receivables from milestones and royalty assets
50,000
Other prepaid and current assets
7,564
Total current assets
418,460
Long-term marketable securities
11,128
Property and equipment, net
5,895
Operating lease assets
24,371
Restricted cash
836
Other assets
24,880
Total assets
485,570
Accounts payable
2,568
Accrued personnel-related expenses
12,592
Accrued clinical and development expenses
3,373
Accrued general and administrative expenses
2,052
Operating lease liabilities
10,945
Income tax payable
5,287
Other accrued liabilities
1,485
Total current liabilities
38,302
Long-term operating lease liabilities
31,758
Future royalty payment contingency
32,795
Unrecognized tax benefits
85,679
Other long-term liabilities
313
Ordinary shares, 0.00001 par value per share 200,000 shares authorized 51,069 and 49,471 shares issued and outstanding at december 31, 2025 and december 31, 2024, respectively
1
Additional paid-in capital
1,156,288
Accumulated other comprehensive income
61
Accumulated deficit
-859,627
Total shareholders' equity
296,723
Total liabilities and shareholders' equity
485,570
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$167,806K Short-term marketablesecurities$147,551K Receivables from milestonesand royalty assets$50,000K Receivables fromcollaborative arrangements$45,539K Other prepaid andcurrent assets$7,564K Total current assets$418,460K Other assets$24,880K Operating lease assets$24,371K Long-term marketablesecurities$11,128K Property and equipment,net$5,895K Restricted cash$836K Total assets$485,570K Total liabilities andshareholders' equity$485,570K Total shareholders'equity$296,723K Unrecognized tax benefits$85,679K Total currentliabilities$38,302K Future royalty paymentcontingency$32,795K Long-term operating leaseliabilities$31,758K Other long-termliabilities$313K Accumulated deficit-$859,627K Additional paid-in capital$1,156,288K Accruedpersonnel-related expenses$12,592K Operating leaseliabilities$10,945K Income tax payable$5,287K Accrued clinical anddevelopment expenses$3,373K Accounts payable$2,568K Accrued general andadministrative expenses$2,052K Other accruedliabilities$1,485K Accumulated othercomprehensive income$61K Ordinary shares, 0.00001par value per share...$1K

Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma, Inc. (TBPH)